This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinicaltrial data published in the European Journal of Pain. Additional information regarding cannabinoids and pain appears online h ere.
The study is expected to be the world’s first Phase 2a clinicaltrial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The open-label Phase 2a clinicaltrial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.
The objective of the survey published in December 2020 explored “ the effect that medical cannabis has on prescription opioid medication usage for the treatment of chronicpain at three medical cannabis practice sites ”. The Effect of Medical Cannabis on Prescription Opioids.
The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronicpain. Los Angeles, California. www.InvestorBrandNetwork.com.
Neuropathic pain is chronicpain made prevalent by tissue injury. Other symptoms include : Pain or cramping, especially of the hands, feet or calf muscles. The American ChronicPain Association (ACPA) states that “with neuropathic pain, the nerve fibers themselves might be damaged, dysfunctional, or injured.
The study, titled Pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronicpain: A randomized, double-blinded, placebo-controlled trial , was first published by NORML. “The 1mg dose showed a significant pain decrease compared to the placebo.
BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, will present at the H.C. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.
Because there is limited or conflicting research about “the true nature of traumatic brain injury and how it causes chronic degenerative problems,” treatment can be a challenging process for many patients. This means that often pharmaceutical medications are experimental. Relieve pain, inflammation and nausea.
Patent protects methods of administering MYMD-1 for treating disorders associated with chronic inflammation, with a focus on fibrosis and asthma. BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.
She is the medical director of Canna-Centers Wellness & Education and the clinical advisor to Cannformatics. She is also the author of Cannabis is Medicine: How Medical Cannabis and CBD are Healing Everything from Anxiety to ChronicPain. Remember, the pharmaceutical model is “this medicine addresses this specific target.”
BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.
However, many of these pharmaceutical medications can just induce more unpleasant, debilitating effects on those who are ill. Depending on the type of terminal illness diagnosed by the doctor, there are numerous pharmaceutical and conventional medications provided for patients to treat the symptoms that come with a terminal illness.
Professor Luke Henderson is set to be the study’s lead investigator and he explains that the unfortunate truth for more than half of spinal cord injury patients is the development of chronicpain. Chronicpain is common, expensive, and challenging to treat, which is why many individuals have turned to cannabis.
The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon.
Clinicaltrials have shown that small doses of CBD help people to manage their social anxiety. If you suffer from spinal cord injuries, multiple sclerosis-associated pain, chronicpain, or regular muscle pain, then you’ll benefit from taking CBD. It’s also usually organic, natural, and free from chemicals.
However, with medical cannabis continuing to spread through the country—and with more and more research pointing to its benefits for everything from chronicpain and sleep problems to anxiety and arthritis—the tide seems to be turning. Numerous studies point to that fact, especially in cases surrounding chronicpain and discomfort.
Pharmaceutical companies use artificial intelligence (AI) to sort through reams of scientific data to find potentially effective active ingredients to be developed into approved drugs. Taking the doctor-patient use of RYAH devices one step further, organizations conducting clinicaltrials are finding value in the company’s offerings.
Study Results Indicate SCI-160 Has A Significant Analgesic Effect on Acute and ChronicPain. Key findings from the pre-clinicaltrial are as follows: SCI-160 significantly alleviates pain up to 6 hours after injection as compared with vehicle-treated animals. TEL AVIV, Israel , Aug.
.–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinicaltrial agreement with Altasciences Company, Inc.,
From 2015 to 2018, the number of clinics increased from 60 to 300; that number is undoubtedly higher today. People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. So, how does one lawfully open and operate a ketamine clinic for infusion therapy given the foregoing?
Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.).
BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. About Supera-CBD.
The results showed that whole-plant hemp oil reduced mechanical pain sensitivity 10-fold for several hours in mice with chronic post-operative neuropathic pain. A chronic neuropathic pain model was used that exposed mice to post-operative neuropathic pain equivalent to several years of chronicpain in human patients.
New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. We believe that the new data we are revealing today is an extraordinary achievement in the field of pharmaceutical cannabinoids,” said Adam Kaplin, M.D.,
MyMD to launch two simultaneous Phase 2 trials during the current quarter to study MYMD-1’s function in extending healthy lifespan and treating COVID-19-associated depression. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.
BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m.
BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., MyMD Pharmaceuticals, Inc.
A 2020 study reported that the top conditions reported amongst veterans include chronicpain , sleep problems , anxiety , and depression. The Endocannabinoid System in our bodies makes cannabis a viable alternative to pharmaceutical medications due to its function of promoting homeostasis in the body.
GW Pharmaceuticals. The steadily aging population across the globe has played a significant role in driving the demand for medical cannabis as geriatric patients are more likely to develop chronic illnesses and require more physician visits. GW Pharmaceuticals. ChronicPain. during 2021-2026. Companies Mentioned.
–(BUSINESS WIRE)– #pharma –Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX) achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below. “I About Virpax Pharmaceuticals. BERWYN, Pa.–(BUSINESS
BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its investment company Oravax Medical Inc. Oravax is also preparing to commence clinicaltrials in Israel.”.
BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its investment company Oravax Medical Inc. Oravax is also preparing to commence clinicaltrials in Israel.
Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. tumor necrosis factor receptor I (TNFRI) and IL-6.
–(BUSINESS WIRE)– #earnings — Virpax ® Pharmaceuticals, Inc. We continue to enhance our product pipeline, and because of our unique delivery technologies we have expanded our targeted indications beyond pain to include Central Nervous System (CNS) disorders and anti-viral indications. “Our
BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.
The device uses a number of proprietary technologies, including its preloaded cartridges, vaporchips that meet uniform amount pharmaceutical standards, and the 100 microgram resolution metered-dose delivery. If it wasn’t obvious, the Syqe inhaler isn’t the sort of device you’ll find at your head shop next to the dab rigs and Polar Bear Snuff.
From its anti-inflammatory properties to its ability to alleviate pain, CBD shows promise in addressing various health conditions. Studies have suggested that CBD may help manage chronicpain, reduce anxiety and depression, alleviate symptoms of epilepsy, and even aid in cancer treatment.
BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.
. “We can now concentrate all our energies on advancing our plant-inspired, biopharmaceutical research and development programs into human clinicaltrials.” and three international patents that have been issued to protect therapeutic mixtures for Parkinson’s disease, chronicpain, hyperinflammation, and heart disease.
.–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. This data should strengthen the Company’s IND filing in advance of the anticipated start of first-in-human clinicaltrials. About Virpax Pharmaceuticals. Mack, Chairman and CEO of Virpax. For more information, please visit www.virpaxpharma.com.
Medical marijuana is a potential treatment for insomnia, and it offers an alternative to traditional pharmaceuticals. Chronicpain conditions, such as arthritis or back pain, can cause discomfort that interferes with sleep. excessive noise or light), can also disrupt the natural sleep-wake cycle.
First, plenty of pharmaceutical drugs, that we broadly accept as legitimate medicine, received approval from the U.S. Just because we don’t yet have clinicaltrial results that confirm medical cannabis relieves pain, or eases insomnia, or reduces inflammation, etc., There are two things wrong with this argument.
There’s a consensus among clinicians that existing pharmaceutical treatments such as antidepressant simply do not work. For more on marijuana vs. pharmaceutical medication, see: How Marijuana Helps PTSD. Medical marijuana may also play a role in treating nightmares.
The increasing research on medical marijuana shows its therapeutic value for a range of health conditions, including chronicpain, cancer, arthritis, diabetes, depression, anxiety, and many more. Cannabis oil: TO Pharmaceuticals TO Pharma is developing next-generation cannabinoid therapies for debilitating diseases. Key Players.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content